Results for deferoxamine translation from English to Maltese

half of deferoxamine dose
nofs id-doża ta’ deferoxamine

one third of deferoxamine dose
terz tad-doża ta’ deferoxamine

for patients well managed on deferoxamine
għal pazjenti kkontrollati sew b’deferoxamine

the product information of deferoxamine should be consulted.
it-tagħrif tal-prodott ta’ deferoxamine għandu jiġi kkonsultat.

therefore deferiprone at the recommended dose could be less effective than deferoxamine.
għalhekk deferiprone fid- doża rakkomandata jista ’ jkun inqas effettiv minn deferoxamine.

in one study of two-year duration deferiprone was compared to deferoxamine.
fi studju minnhom li dam sejjer sentejn, deferiprone tqabbel ma ’ deferoxamine.

the main study of effectiveness compared exjade with deferoxamine in 591 patients with beta thalassaemia major.
l- istudju ewlieni tal- effikaċja qabbel exjade ma 'deferoxamine f' 591 pazjent bil- beta talassemija major.

ferriprox is used when deferoxamine (another medicine used to treat iron overload) cannot be used.
ferriprox jintuża meta ma jkunx jista ’ jintuża deferoxamine (mediċina oħra użata fit- trattament ta ’ l- akkumulazzjoni eċċessiva tal- ħadid.

ferriprox is indicated for the treatment of iron overload in patients with thalassaemia major when deferoxamine therapy is contraindicated or inadequate.
ferriprox hu indikat għall- kura ta ’ livelli eċċessivi ta ’ ħadid f’ pazjenti li għandhom talessimja maġġura meta t- terapija b’ deferoxamine hi kontra- indikata jew inadegwata.

in the initial study comparing ferriprox with deferoxamine, the average blood ferritin levels were similar in the two treatment groups.
fl-istudju inizjali li qabbel ferriprox ma’ deferossamina, il-livelli medji ta’ ferritina fid-demm kienu simili fiż-żewġ gruppi ta’ kura.

however, there were too few patients in the study to prove whether or not such a schedule is as effective as deferoxamine taken on its own.
madankollu, in-numru ta’ pazjenti li ħadu sehem fl- istudju kien baxx wisq biex juri li din l-iskeda kienet effikaċi daqs deferossamina meħudha waħedha jew le.

based on the reported adverse interaction that can occur between deferoxamine and vitamin c, caution should be used when administering deferiprone and vitamin c concurrently.
skond l-interazzjoni avversa rrappurtata li tista’ sseħħ bejn deferoxamine u l-vitamina Ċ, għandha tingħata attenzjoni meta deferiporne u l-vitamina Ċ jingħataw ma’ xulxin.

this imbalance occurred because patients on deferoxamine were allowed to remain on their pre-study dose even if it was higher than the protocol specified dose.
dan l-iżbilanċ seħħ minħabba li l-pazjenti li kienu fuq deferoxamine tħallew fuq id-doża ta’ qabel ma beda l-istudju anki jekk kienet ogħla minn dik speċifikata fil-protokoll.

an additional study looked at the effectiveness of exjade in 184 patients who could not be treated with deferoxamine, including patients with beta thalassaemia major and with other types of anaemia.
studju addizzjonali eżamina l- effikaċja ta 'exjade f' 184 pazjent li ma setgħux jiġu ttrattati b' deferoxamine, fosthom pazjenti bil- beta talassemija major u tipi oħrajn ta' anemija.

in the additional study, more than half of the patients who could not be treated with deferoxamine had responded to treatment with exjade after a year, including patients aged between two and five years.
fl- istudju addizzjonali, iktar minn nofs il- pazjenti li ma setgħux jiġu ttrattati b' deferoxamine irrispondew għat- trattament b' exjade wara sena, fosthom pazjenti b' età bejn sentejn u ħames snin.

however, when looking at the 381 patients who had particularly high levels of iron in their liver at the beginning of the study and who received comparable amounts of exjade or deferoxamine, the two medicines were as effective as each other.
madankollu, meta wieħed iħares lejn it- 381 pazjent li fil- bidu tal- istudju kellhom livelli partikolarment għoljin ta 'ħadid fil- fwied u li kienu ħadu ammonti ta' exjade jew deferoxamine komparabbli, iż- żewġ mediċini rriżultaw effikaċi daqs xulxin.

at the end of the main study, 53% of the patients receiving exjade had shown a sufficient response to treatment, compared with 66% of the patients receiving deferoxamine.
fit- tmiem tal- istudju ewlieni, 53% tal- pazjenti ttrattati b' exjade urew rispons suffiċjenti għat - trattament, meta mqabbel ma '66% tal- pazjenti ttrattati b' deferoxamine.

children aged 2 to 5 years with beta thalassaemia major who receive frequent blood transfusions, when deferoxamine (another medicine used to treat iron overload) cannot be used or is inadequate;
tfal bejn is-sentejn u l-ħames snin li jbatu mill-beta talassemija maġġuri li jingħataw trasfużjonijiet tad-demm b’mod frekwenti, meta d-deferoksamina (mediċina oħra użata fil-kura tal-akkumulu eċċessiv ta’ ħadid) ma tkunx tista’ tintuża jew ma tkunx adegwata;

the safety profile of combination therapy (deferiprone and deferoxamine) observed in clinical trials, post-marketing experience or published literature was consistent with that characterized for monotherapy.
il-profil tas-sigurtà ta’ terapija ta’ kombinazzjoni (deferiprone u deferoxamine) osservat mill-provi kliniċi, esperjenza ta’ wara t-tqegħid fis-suq jew fil-letteratura medika ppubblikata kienet konsistenti ma’ dik karatterizzata għal monoterapija.

20 it appeared from preclinical and clinical studies that exjade could be as active as deferoxamine when used in a dose ratio of 2:1 (i. e. a dose of exjade that is numerically half of the deferoxamine dose).
minn studji ta ’ qabel l- użu kliniku u studji kliniċi deher li exjade jista ’ jkun attiv daqs deferoxamine meta jintuża f’ proporzjon ta ’ doża ta ’ 2: 1 (i. e. doża ta ’ exjade li tiġi numerikament nofs dik tad- doża ta ’ deferoxamine).